Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 2, Pages 335-340Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1055479
Keywords
CD20; multiple myeloma; therapy
Categories
Funding
- Natural Science Foundation of Guangdong, China [S2013010016838]
- Science and Technology Program of Guangdong, China [2014A020212061]
- National Public Health Grand Research Foundation [201202017]
Ask authors/readers for more resources
In order to ascertain clinical characteristics and outcomes of CD20 + multiple myeloma (MM) patients, we retrospectively analyzed 331 newly diagnosed patients with multiple myeloma in our center. The clinical characteristics, cell morphology, immunophenotype, and cytogenetic were different between the CD20 + and CD20 - group. The median course of treatment to >= nCR (near complete recovery) were 4.5 in the CD20+ group and 2 in the CD20 - group. Excluding the IgD type, overall survival (OS) and progression-free survival (PFS) in the CD20 + group were higher than that in the CD20 - group. There were no statistically significant differences in PFS and OS in CD20+ patients after treatment with conventional regimens, novel drugs +/- transplant, nor statistical significance between those with the response >= nCR and > nCR after treatment. In conclusion, CD20-positive myeloma cells are a cluster with heterogenous clinical characteristics, cell morphology, immunophenotype and cytogenetics. For these non-IgD CD20 + MM patients, conventional therapy might be a choice to achieve an ideal outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available